These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18481897)

  • 1. Calcitonin: a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality.
    Karsdal MA; Henriksen K; Arnold M; Christiansen C
    BioDrugs; 2008; 22(3):137-44. PubMed ID: 18481897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral salmon calcitonin--pharmacology in osteoporosis.
    Henriksen K; Bay-Jensen AC; Christiansen C; Karsdal MA
    Expert Opin Biol Ther; 2010 Nov; 10(11):1617-29. PubMed ID: 20932224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term culture of disaggregated rat osteoclasts: inhibition of bone resorption and reduction of osteoclast-like cell number by calcitonin and PTHrP[107-139].
    Fenton AJ; Martin TJ; Nicholson GC
    J Cell Physiol; 1993 Apr; 155(1):1-7. PubMed ID: 8468357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin for osteoporosis and bone pain.
    Mehta NM; Malootian A; Gilligan JP
    Curr Pharm Des; 2003; 9(32):2659-76. PubMed ID: 14529539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nasal calcitonin.
    Silverman SL
    Endocrine; 1997 Apr; 6(2):199-202. PubMed ID: 9225136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation.
    Schaller S; Henriksen K; Sveigaard C; Heegaard AM; Hélix N; Stahlhut M; Ovejero MC; Johansen JV; Solberg H; Andersen TL; Hougaard D; Berryman M; Shiødt CB; Sørensen BH; Lichtenberg J; Christophersen P; Foged NT; Delaissé JM; Engsig MT; Karsdal MA
    J Bone Miner Res; 2004 Jul; 19(7):1144-53. PubMed ID: 15176998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.
    Bandeira L; Lewiecki EM; Bilezikian JP
    Expert Opin Drug Metab Toxicol; 2016 Jun; 12(6):681-9. PubMed ID: 27070719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elcatonin prevents bone loss caused by skeletal unloading by inhibiting preosteoclast fusion through the unloading-induced high expression of calcitonin receptors in bone marrow cells.
    Tsukamoto M; Menuki K; Murai T; Hatakeyama A; Takada S; Furukawa K; Sakai A
    Bone; 2016 Apr; 85():70-80. PubMed ID: 26851124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
    Ma Y; Jee WS; Chen Y; Gasser J; Ke HZ; Li XJ; Kimmel DB
    J Bone Miner Res; 1995 Nov; 10(11):1726-34. PubMed ID: 8592950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The treatment of osteoporosis. Antiresorptive therapy.
    Miller PD
    Clin Lab Med; 2000 Sep; 20(3):603-22, viii. PubMed ID: 10986624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
    Rizzoli R; Sigaud A; Azria M; Herrmann FR
    Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons learned from the development of oral calcitonin: the first tablet formulation of a protein in phase III clinical trials.
    Karsdal MA; Henriksen K; Bay-Jensen AC; Molloy B; Arnold M; John MR; Byrjalsen I; Azria M; Riis BJ; Qvist P; Christiansen C
    J Clin Pharmacol; 2011 Apr; 51(4):460-71. PubMed ID: 20660294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
    Väänänen K
    Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin intranasal--unigene: Salcatonin intranasal--unigene.
    Drugs R D; 2004; 5(2):90-3. PubMed ID: 15293868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of osteoporosis with calcitonin].
    Nakano T
    Nihon Rinsho; 2004 Feb; 62 Suppl 2():423-6. PubMed ID: 15035164
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms underlying the effects of phosphate and calcitonin on bone histology in postmenopausal osteoporosis.
    Marie PJ; Caulin F
    Bone; 1986; 7(1):17-22. PubMed ID: 3964494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hormones and osteoporosis update. Calcitonin, CGRP and bone].
    Ozono K
    Clin Calcium; 2009 Jul; 19(7):929-34. PubMed ID: 19567987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strontium ranelate: a dual mode of action rebalancing bone turnover in favour of bone formation.
    Marie PJ
    Curr Opin Rheumatol; 2006 Jun; 18 Suppl 1():S11-5. PubMed ID: 16735840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.